These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 17467813)

  • 1. Immune response against therapeutic factor VIII in hemophilia A patients--a survey of probable risk factors.
    Dasgupta S; Navarrete AM; Delignat S; Wootla B; Andre S; Nagaraja V; Lacroix-Desmazes S; Kaveri SV
    Immunol Lett; 2007 May; 110(1):23-8. PubMed ID: 17467813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Factor VIII inhibitors: role of von Willebrand factor on the uptake of factor VIII by dendritic cells.
    Kaveri SV; Dasgupta S; Andre S; Navarrete AM; Repessé Y; Wootla B; Lacroix-Desmazes S
    Haemophilia; 2007 Dec; 13 Suppl 5():61-4. PubMed ID: 18078399
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence of factor VIII inhibitors in patients with hemophilia A in Brazil.
    Rieger A; Roisenberg I
    Thromb Haemost; 1999 Mar; 81(3):475-6. PubMed ID: 10102489
    [No Abstract]   [Full Text] [Related]  

  • 4. Factor VIII associated with lipidic nanoparticles retains efficacy in the presence of anti-factor VIII antibodies in hemophilia A mice.
    Shetty KA; Kosloski MP; Mager DE; Balu-Iyer SV
    Biopharm Drug Dispos; 2016 Oct; 37(7):409-420. PubMed ID: 27418232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is a change of factor VIII product a risk factor for the development of a factor VIII inhibitor?
    Yee TT; Lee CA
    Thromb Haemost; 1999 May; 81(5):852. PubMed ID: 10365768
    [No Abstract]   [Full Text] [Related]  

  • 6. Adenovirus-mediated factor VIII gene expression results in attenuated anti-factor VIII-specific immunity in hemophilia A mice compared with factor VIII protein infusion.
    Bristol JA; Gallo-Penn A; Andrews J; Idamakanti N; Kaleko M; Connelly S
    Hum Gene Ther; 2001 Sep; 12(13):1651-61. PubMed ID: 11535168
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying nongenetic risk factors for inhibitor development in severe hemophilia a.
    Gouw SC; Fijnvandraat K
    Semin Thromb Hemost; 2013 Oct; 39(7):740-51. PubMed ID: 24014072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Are low-density lipoprotein receptor-related protein 1 or non-neutralizing antibodies predictors of FVIII in vivo recovery in haemophilia A patients?
    Clere AS; Diaz I; Lebreton A; Lavigne-Lissalde G; Schved JF; Biron-Andreani C
    Haemophilia; 2014 Nov; 20(6):e406-8. PubMed ID: 25311419
    [No Abstract]   [Full Text] [Related]  

  • 9. Treatment of patients with hemophilia A and inhibitors to factor FVIII with cimetidine.
    Ambriz Fernandez R; Quintana Gonzalez S; Martinez Murillo C; Dominguez Garcia V; Rodriguez Moyado H; Collazo Jaloma J
    Arch Med Res; 1996; 27(1):15-8. PubMed ID: 8867361
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early eradication of factor VIII inhibitor in patients with congenital hemophilia A by immune tolerance induction with a high dose of immunoglobulin.
    Mizoguchi Y; Furue A; Kagawa R; Chijimatsu I; Tomioka K; Shimomura M; Imanaka Y; Nishimura S; Saito S; Miki M; Ono A; Konishi N; Kawaguchi H; Kobayashi M
    Int J Hematol; 2016 Apr; 103(4):473-7. PubMed ID: 26830966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Editorial: Tolerating Factor VIII: Novel Strategies to Prevent and Reverse Neutralizing Anti-FVIII Antibodies.
    Lacroix-Desmazes S; Pratt KP
    Front Immunol; 2020; 11():639386. PubMed ID: 33569066
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of immunomodulation in the management of factor VIII inhibitors.
    Lillicrap D
    Hematology Am Soc Hematol Educ Program; 2006; ():421-5. PubMed ID: 17124093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of a novel ELISA screening test for detection of factor VIII inhibitory antibodies in haemophiliacs.
    Martin PG; Sukhu K; Chambers E; Giangrande PL
    Clin Lab Haematol; 1999 Apr; 21(2):125-8. PubMed ID: 10342072
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The multifactorial etiology of inhibitor development in hemophilia: genetics and environment.
    Gouw SC; van den Berg HM
    Semin Thromb Hemost; 2009 Nov; 35(8):723-34. PubMed ID: 20169509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Haemophilic patients with inhibitors to factor VIII or IX: variables affecting treatment response.
    Penner JA
    Haemophilia; 2001 Jan; 7(1):103-8. PubMed ID: 11136390
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of factor VIII inhibitors.
    Dimichele DM
    Int J Hematol; 2006 Feb; 83(2):119-25. PubMed ID: 16513529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Inhibitory antibodies in hemophilia A.
    Pratt KP
    Curr Opin Hematol; 2012 Sep; 19(5):399-405. PubMed ID: 22814650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics.
    Kahle J; Orlowski A; Stichel D; Healey JF; Parker ET; Donfield SM; Astermark J; Berntorp E; Lollar P; Schwabe D; Königs C
    Haemophilia; 2017 Mar; 23(2):292-299. PubMed ID: 27862687
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The natural history of the immune response to exogenous factor VIII in severe haemophilia A.
    Scandella D; Mondorf W; Klinge J
    Haemophilia; 1998 Jul; 4(4):546-51. PubMed ID: 9873792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A.
    Peyron I; Dimitrov JD; Delignat S; Gangadharan B; Srivastava A; Kaveri SV; Lacroix-Desmazes S
    Cell Immunol; 2018 Mar; 325():64-68. PubMed ID: 29395036
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.